|
1
|
Stewart EL, Tan SZ, Liu G and Tsao MS:
Known and putative mechanisms of resistance to EGFR targeted
therapies in NSCLC patients with EGFR mutations - a review. Transl
Lung Cancer Res. 4:67–81. 2015.PubMed/NCBI
|
|
2
|
Jakobsen KR, Demuth C, Sorensen BS and
Nielsen AL: The role of epithelial to mesenchymal transition in
resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer. Transl Lung Cancer Res.
5:172–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suda K, Tomizawa K, Fujii M, Murakami H,
Osada H, Maehara Y, Yatabe Y, Sekido Y and Mitsudomi T: Epithelial
to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuo CH, Lin SM, Lee KY, Chung FT, Hsieh
MH, Fang YF, Yu CT and Kuo HP: Subsequent chemotherapy improves
survival outcome in advanced non-small-cell lung cancer with
acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer.
11:51–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Molina-Vila MA, Taron M,
Bertran-Alamillo J, Mayo C, Vergnenegre A, De Marinis F, Massuti B,
De Castro J, Gervais R, et al: EGFR compound mutants and survival
on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in
the EURTAC study. J Clin Oncol. 30 15 Suppl:S75222012.
|
|
6
|
Shintani Y, Okimura A, Sato K, Nakagiri T,
Kadota Y, Inoue M, Sawabata N, Minami M, Ikeda N, Kawahara K, et
al: Epithelial to mesenchymal transition is a determinant of
sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann
Thorac Surg. 92:1794–1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou J, Wang J, Zeng Y, Zhang X, Hu Q,
Zheng J, Chen B, Xie B and Zhang WM: Implication of
epithelial-mesenchymal transition in IGF1R-induced resistance to
EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget.
6:44332–44345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen G, Kronenberger P, Teugels E, Umelo
IA and De Grève J: Effect of siRNAs targeting the EGFR T790M
mutation in a non-small cell lung cancer cell line resistant to
EGFR tyrosine kinase inhibitors and combination with various
agents. Biochem Biophys Res Commun. 431:623–629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen G, Kronenberger P, Teugels E, Umelo
IA and De Grève J: Targeting the epidermal growth factor receptor
in non-small cell lung cancer cells: The effect of combining RNA
interference with tyrosine kinase inhibitors or cetuximab. BMC Med.
10:282012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen G, Kronenberger P, Umelo IA, Teugels
E and De Grève J: Quantification of epidermal growth factor
receptor T790M mutant transcripts in lung cancer cells by real-time
reverse transcriptase-quantitative polymerase chain reaction. Anal
Biochem. 398:266–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ogino A, Kitao H, Hirano S, Uchida A,
Ishiai M, Kozuki T, Takigawa N, Takata M, Kiura K and Tanimoto M:
Emergence of epidermal growth factor receptor T790M mutation during
chronic exposure to gefitinib in a non small cell lung cancer cell
line. Cancer Res. 67:7807–7814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng H, An SJ, Dong S, Zhang YF, Zhang
XC, Chen ZH, Jian Su and Wu YL: Molecular mechanism of the
schedule-dependent synergistic interaction in EGFR-mutant non-small
cell lung cancer cell lines treated with paclitaxel and gefitinib.
J Hematol Oncol. 4:52011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition
derived from repeated exposure to gefitinib determines the
sensitivity to EGFR inhibitors in A549, a non-small cell lung
cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mittal V: Epithelial mesenchymal
transition in aggressive lung cancers. Adv Exp Med Biol. 890:37–56.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin H, Wang Y, Chen W, Zhong S, Liu Z and
Zhao J: Drug-resistant CXCR4-positive cells have the molecular
characteristics of EMT in NSCLC. Gene. 594:23–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rastogi I, Rajanna S, Webb A, Chhabra G,
Foster B, Webb B and Puri N: Mechanism of c-Met and EGFR tyrosine
kinase inhibitor resistance through epithelial mesenchymal
transition in non-small cell lung cancer. Biochem Biophys Res
Commun. 477:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
20
|
Shien K, Toyooka S, Yamamoto H, Soh J,
Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, et al:
Acquired resistance to EGFR inhibitors is associated with a
manifestation of stem cell-like properties in cancer cells. Cancer
Res. 73:3051–3061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Floor S, van Staveren WC, Larsimont D,
Dumont JE and Maenhaut C: Cancer cells in epithelial-to-mesenchymal
transition and tumor-propagating-cancer stem cells: Distinct,
overlapping or same populations. Oncogene. 30:4609–4621. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pirozzi G, Tirino V, Camerlingo R, Franco
R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N and Rocco
G: Epithelial to mesenchymal transition by TGFβ-1 induction
increases stemness characteristics in primary non small cell lung
cancer cell line. PLoS One. 6:e215482011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu J, Qiu M, Jiang F, Zhang S, Yang X,
Wang J, Xu L and Yin R: MiR-145 regulates cancer stem-like
properties and epithelial-to-mesenchymal transition in lung
adenocarcinoma-initiating cells. Tumour Biol. 35:8953–8961. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuwano M, Sonoda K, Murakami Y, Watari K
and Ono M: Overcoming drug resistance to receptor tyrosine kinase
inhibitors: Learning from lung cancer. Pharmacol Ther. 161:97–110.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pirazzoli V, Ayeni D, Meador CB,
Sanganahalli BG, Hyder F, de Stanchina E, Goldberg SB, Pao W and
Politi K: Afatinib plus cetuximab delays resistance compared to
single-agent erlotinib or afatinib in mouse models of TKI-Naïve
EGFR L858R-induced lung adenocarcinoma. Clin Cancer Res.
22:426–435. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Singh R, Wang L, Nilsson M,
Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, et al:
Polo-like kinase 1 inhibition diminishes acquired resistance to
epidermal growth factor receptor inhibition in non-small cell lung
cancer with T790M mutations. Oncotarget. 7:47998–48010.
2016.PubMed/NCBI
|
|
29
|
Leung EL, Fan XX, Wong MP, Jiang ZH, Liu
ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin VP and Liu L: Targeting
tyrosine kinase inhibitor-resistant Non-small cell lung cancer by
inducing epidermal growth factor receptor degradation via
methionine 790 oxidation. Antioxid Redox Signal. 24:263–279. 2016.
View Article : Google Scholar : PubMed/NCBI
|
